SFBC學術報告 （線上）

報告題目：Zwitterionic Biomaterials for Safe and Efficacious Delivery of Biologics

報告人： 李博文 博士

                美國麻省理工學院科赫癌症綜合研究所

報告時間：2020年7月3日   上午9:00—10：30

會議室鍊接：https://meeting.tencent.com/s/5JNmEA1USwJw

會議 ID：500 529 814

報告摘要：Biologics such as peptides, proteins, nucleic acids, and CRISPR-Cas9 genome editing machinery represent the cutting edge of modern medicine and are driving growth in the pharmaceuticals market. However, the development and use of biologic drugs entail unique challenges and risks. For example, therapeutic proteins are subject to immune surveillance in the human body and ensuing anti-protein antibodies can lead to a wide range of problems including altered pharmacokinetics (PK) and pharmacodynamics (PD), loss of efficacy, and even life-threating complications. To render biologics more suitable for clinical use, conjugation of poly (ethylene glycol) (PEG), a non-ionic polymer, has been widely employed as the “gold standard” for immunogenicity mitigation and PK/PD improvement. Up to now, more than ten PEGylated pharmaceutical products have been approved by the U.S. FDA with many more currently in clinical pipelines. Unfortunately, PEG has been found to induce anti-PEG antibodies, causing accelerated blood clearance of PEGylated therapeutics and even lethal adverse reactions such as anaphylaxis. In this seminar, I will introduce zwitterionic biomaterials as a class of promising PEG alternatives to overcome the “PEGylation dilemma”. First, I will discuss a fundamental study on the immunological property of zwitterionic biomaterials. Second, I will describe applications of zwitterionic biomaterials in drug delivery and nanomedicine, focusing on how to achieve safe and effective delivery of biologics. I will describe several poly(zwitterion)-based delivery platforms for highly immunogenic protein drugs, which have manifested to eliminate the unwanted immune response, ameliorate the PK/PD, and enhance the efficacy in clinical-relevant settings. Lastly, I will present the recent development of immunomodulatory zwitterionic polymers, providing new insights into the rational design of functional biomaterials for drug delivery. In summary, my research experiences and scientific contributions in zwitterionic biomaterials have laid a foundation for my long-term research goal of developing novel biomaterial-aided drug delivery systems for large and complex biologics to resolve unmet medical needs with the eventual goal of enabling new therapies for poorly treated devastating diseases.

附：報告人簡介